Moderna's shares have surged by over 24% in the past week, propelled by resilient COVID vaccine sales and favorable quarterly results. The stock further jumped more than 6% following the FDA's unexpected decision to review its new seasonal flu vaccine candidate, reversing a previous rejection. Despite ongoing legal challenges, including a lawsuit from BioNTech, Moderna's financial position remains strong, bolstered by a significant drop in operating expenses and a promising pipeline of future products.
“Moderna · beats · quarterly revenue estimates · on resilient sales of COVID shot”
“Moderna · beats · quarterly revenue estimates · resilient sales of COVID shot”
“Moderna (MRNA) · is up more than · percent · +2%”
“Moderna · is up · more than +2%”
“Moderna (MRNA) · is up · more than +2% · +2%”
“Moderna · gained · +24.33% · last week”
“Moderna · beats · quarterly revenue estimates · on resilient sales of COVID shot”
“Moderna · gained · 24.33% · true”
“Moderna shares · jumped · more than 6% · after FDA agreed to review flu vaccine”
“Moderna · proposed regulatory pathway based on · age for flu vaccine approval · full approval for adults 50 to 64 years and accelerated approval for adults 65 and older”
“Moderna · gained · +24.33% · last week”
“Moderna · gained · +24.33% · increase”
